42 related articles for article (PubMed ID: 18064564)
1. Potentiation of tumor necrosis factor-induced NF-kappa B activation by deacetylase inhibitors is associated with a delayed cytoplasmic reappearance of I kappa B alpha.
Adam E; Quivy V; Bex F; Chariot A; Collette Y; Vanhulle C; Schoonbroodt S; Goffin V; Nguyên TL; Gloire G; Carrard G; Friguet B; De Launoit Y; Burny A; Bours V; Piette J; Van Lint C
Mol Cell Biol; 2003 Sep; 23(17):6200-9. PubMed ID: 12917341
[TBL] [Abstract][Full Text] [Related]
2. Synergistic, cytotoxic and apoptotic activities of olmesartan with NF-κB inhibitor against HeLa human cell line.
Bakhtiari E; Hosseini A; Boroushaki MT; Mousavi SH
Toxicol Mech Methods; 2015; 25(8):614-21. PubMed ID: 26330000
[TBL] [Abstract][Full Text] [Related]
3. NF-kappaB inhibition is involved in tobacco smoke-induced apoptosis in the lungs of rats.
Zhong CY; Zhou YM; Pinkerton KE
Toxicol Appl Pharmacol; 2008 Jul; 230(2):150-8. PubMed ID: 18355884
[TBL] [Abstract][Full Text] [Related]
4. NF-κB Signaling in Tumor Pathways Focusing on Breast and Ovarian Cancer.
Devanaboyina M; Kaur J; Whiteley E; Lin L; Einloth K; Morand S; Stanbery L; Hamouda D; Nemunaitis J
Oncol Rev; 2022; 16():10568. PubMed ID: 36531159
[TBL] [Abstract][Full Text] [Related]
5. Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities.
Garmpis N; Damaskos C; Garmpi A; Georgakopoulou VE; Sarantis P; Antoniou EA; Karamouzis MV; Nonni A; Schizas D; Diamantis E; Koustas E; Farmaki P; Syllaios A; Patsouras A; Kontzoglou K; Trakas N; Dimitroulis D
J Pers Med; 2021 Mar; 11(3):. PubMed ID: 33809844
[TBL] [Abstract][Full Text] [Related]
6. Enhanced cytotoxicity of human hepatocellular carcinoma cells following pretreatment with sorafenib combined with trichostatin A.
Chen JC; Chuang HY; Liao YJ; Hsu FT; Chen YC; Wang WH; Hwang JJ
Oncol Lett; 2019 Jan; 17(1):638-645. PubMed ID: 30655811
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effects of combined treatment with histone deacetylase inhibitor suberoylanilide hydroxamic acid and TRAIL on human breast cancer cells.
Zhou W; Feng X; Han Han ; Guo S; Wang G
Sci Rep; 2016 Jun; 6():28004. PubMed ID: 27292433
[TBL] [Abstract][Full Text] [Related]
8. Targeting the NFκB signaling pathways for breast cancer prevention and therapy.
Wang W; Nag SA; Zhang R
Curr Med Chem; 2015; 22(2):264-89. PubMed ID: 25386819
[TBL] [Abstract][Full Text] [Related]
9. Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system.
Budman DR; Calabro A; Rosen L; Lesser M
Anticancer Drugs; 2012 Mar; 23(3):272-9. PubMed ID: 23427335
[TBL] [Abstract][Full Text] [Related]
10. PAX7-FKHR fusion gene inhibits myogenic differentiation via NF-kappaB upregulation.
Charytonowicz E; Matushansky I; Doménech JD; Castillo-Martín M; Ladanyi M; Cordon-Cardo C; Ziman M
Clin Transl Oncol; 2012 Mar; 14(3):197-206. PubMed ID: 22374423
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors: emerging mechanisms of resistance.
Robey RW; Chakraborty AR; Basseville A; Luchenko V; Bahr J; Zhan Z; Bates SE
Mol Pharm; 2011 Dec; 8(6):2021-31. PubMed ID: 21899343
[TBL] [Abstract][Full Text] [Related]
12. CCR2 plays a critical role in dendritic cell maturation: possible role of CCL2 and NF-kappa B.
Jimenez F; Quinones MP; Martinez HG; Estrada CA; Clark K; Garavito E; Ibarra J; Melby PC; Ahuja SS
J Immunol; 2010 May; 184(10):5571-81. PubMed ID: 20404272
[TBL] [Abstract][Full Text] [Related]
13. Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer.
Brahemi G; Kona FR; Fiasella A; Buac D; Soukupová J; Brancale A; Burger AM; Westwell AD
J Med Chem; 2010 Apr; 53(7):2757-65. PubMed ID: 20222671
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors: current status and overview of recent clinical trials.
Ma X; Ezzeldin HH; Diasio RB
Drugs; 2009 Oct; 69(14):1911-34. PubMed ID: 19747008
[TBL] [Abstract][Full Text] [Related]
15. Cell cycle-dependent effects of 3,3'-diindolylmethane on proliferation and apoptosis of prostate cancer cells.
Chinnakannu K; Chen D; Li Y; Wang Z; Dou QP; Reddy GP; Sarkar FH
J Cell Physiol; 2009 Apr; 219(1):94-9. PubMed ID: 19062173
[TBL] [Abstract][Full Text] [Related]
16. Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma.
Wolff JE; Kramm C; Kortmann RD; Pietsch T; Rutkowski S; Jorch N; Gnekow A; Driever PH
J Neurooncol; 2008 Dec; 90(3):309-14. PubMed ID: 18679579
[TBL] [Abstract][Full Text] [Related]
17. Molecular targeted therapies for breast cancer treatment.
Schlotter CM; Vogt U; Allgayer H; Brandt B
Breast Cancer Res; 2008; 10(4):211. PubMed ID: 18671839
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells.
Domingo-Domènech J; Pippa R; Tápia M; Gascón P; Bachs O; Bosch M
Breast Cancer Res Treat; 2008 Nov; 112(1):53-62. PubMed ID: 18064564
[TBL] [Abstract][Full Text] [Related]
19. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.
Dai Y; Rahmani M; Dent P; Grant S
Mol Cell Biol; 2005 Jul; 25(13):5429-44. PubMed ID: 15964800
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
